The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
< 0.100 Eu/µg
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Constituents: 5mM Sodium citrate, pH 4.0
Endotoxin level is less than 0.1 ng per µg (1EU/µg)
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. This solution can then be diluted into other aqueous buffers and stored at 4oC for 1 week or -20oC for future use
B cell activating factor receptor
B-cell-activating factor receptor
BLyS receptor 3
Tumor necrosis factor receptor subunit member 13C
Tumor necrosis factor receptor superfamily member 13C
B-cell receptor specific for TNFSF13B/TALL1/BAFF/BLyS. Promotes the survival of mature B-cells and the B-cell response.
Highly expressed in spleen and lymph node, and in resting B-cells. Detected at lower levels in activated B-cells, resting CD4+ T-cells, in thymus and peripheral blood leukocytes.
Involvement in disease
Defects in TNFRSF13C are the cause of immunodeficiency common variable type 4 (CVID4) [MIM:613494]; also called antibody deficiency due to BAFFR defect. CVID4 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.